SHIM
DSGN icon

Stone House Investment Management’s Design Therapeutics DSGN Stock Holding History

Stone House Investment Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.46K Hold
239
– – ﹤0.01% 630
2026
Q1 		$2.54K Buy
+239
New +$2.42K ﹤0.01% 559

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Logos Global Management
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Stone House Investment Management's DSGN Position: Q2 2026 in Review

Stone House Investment Management held its Design Therapeutics (DSGN) position steady in Q2 2026 at 239 shares worth $3.46K. The position accounts for ﹤0.01% of the portfolio, ranked #630.

Stone House Investment Management first reported a position in DSGN in Q1 2026 and has held it in 2 quarters since. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Stone House Investment Management held 239 shares of Design Therapeutics worth $3.46K as of Q2 2026.
  • Stone House Investment Management left its Design Therapeutics share count unchanged in Q2 2026.
  • Design Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #630 holding.
  • Stone House Investment Management first reported a position in Design Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.